Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Cue Biopharma (CUE) stocks in Canada
Learn how to easily invest in Cue Biopharma stocks.
Cue Biopharma is a biotechnology business based in the US. Cue Biopharma stocks (CUE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.01 – an increase of 20.05% over the previous week. Cue Biopharma employs 50 staff and has a trailing 12-month revenue of around $7.2 million.
How to buy shares in Cue Biopharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CUE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Cue Biopharma?
- Has coronavirus impacted Cue Biopharma shares?
- Cue Biopharma shares summary
- Compare share dealing platforms
- Is Cue Biopharma stock a buy or sell?
- Cue Biopharma performance over time
- Cue Biopharma's financials
- How volatile are Cue Biopharma shares?
- Does Cue Biopharma pay a dividend?
- Other common questions
Cue Biopharma stock price (NASDAQ:CUE)Use our graph to track the performance of CUE stocks over time.
Cue Biopharma shares at a glance
|Latest market close||$10.60|
|52-week range||$8.17 - $18.42|
|50-day moving average||$12.08|
|200-day moving average||$12.32|
|Wall St. target price||$28.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.52|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Cue Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cue Biopharma price performance over time
|1 week (2022-01-21)||17.78%|
|1 month (2021-12-24)||N/A|
|3 months (2021-10-28)||-13.61%|
|6 months (2021-07-28)||-3.37%|
|1 year (2021-01-28)||-22.00%|
|2 years (2020-01-28)||-34.41%|
|3 years (2019-01-28)||104.24%|
|5 years (2017-01-24)||N/A|
Cue Biopharma financials
|Revenue TTM||$7.2 million|
|Gross profit TTM||$-30,391,380|
|Return on assets TTM||-31.53%|
|Return on equity TTM||-62.06%|
|Market capitalisation||$275 million|
TTM: trailing 12 months
Cue Biopharma share dividends
We're not expecting Cue Biopharma to pay a dividend over the next 12 months.
Cue Biopharma share price volatility
Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $8.172 up to $18.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.4366. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cue Biopharma overview
Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine.
Stocks similar to Cue Biopharma
Cue Biopharma in the news
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study - Benzinga
Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer - Benzinga
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Haemonetics Corporation stock in Canada
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Go Auto Review
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.